These recommendations provide standard requirements for general practice and for clinical trials. However, to accelerate progress in research the panel strongly recommends entry of AML patients on clinical trials, and storage of biosamples to enable correlative laboratory studies. The following statements and recommendations are based on studies that predominantly were performed in the United States and Europe. Specific dosages and interventions may vary among different countries and populations.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.